An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation
stevepb / Pixabay

An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation

The US FDA has awarded Breakthrough Therapy Designation to encorafenib (braftoviTM) combined with binimetinib (mektovi®) and cetuximab for use as an investigational (not FDA-approved) treatment of BRAFV600E–mutant metastatic colorectal cancer.…

Continue Reading An Experimental Drug Combination Treatment for Certain Bowel Cancers Has Been Granted Breakthrough Therapy Designation